Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out
Executive Summary
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.